SLC5A2 and myocardial infarction: Previous studies have demonstrated that in the early stage of AMI, SGLT2 inhibitor use reduces the myocardial infarct size through activation of signal transducer and activator of transcription 3 and downregulation of inflammatory responses in the infarcted myocardium (23).